1. Home
  2. GBX vs ANAB Comparison

GBX vs ANAB Comparison

Compare GBX & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenbrier Companies Inc. (The)

GBX

Greenbrier Companies Inc. (The)

HOLD

Current Price

$48.97

Market Cap

1.4B

Sector

Industrials

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$49.11

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GBX
ANAB
Founded
1974
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Railroads
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
GBX
ANAB
Price
$48.97
$49.11
Analyst Decision
Sell
Buy
Analyst Count
2
12
Target Price
$45.00
$58.09
AVG Volume (30 Days)
497.0K
522.1K
Earning Date
01-08-2026
02-26-2026
Dividend Yield
2.65%
N/A
EPS Growth
0.79
N/A
EPS
5.77
N/A
Revenue
$3,070,400,000.00
$169,467,000.00
Revenue This Year
N/A
$135.45
Revenue Next Year
N/A
N/A
P/E Ratio
$8.39
N/A
Revenue Growth
N/A
196.42
52 Week Low
$37.77
$12.21
52 Week High
$71.06
$52.47

Technical Indicators

Market Signals
Indicator
GBX
ANAB
Relative Strength Index (RSI) 56.10 61.08
Support Level $47.18 $42.50
Resistance Level $49.40 $50.00
Average True Range (ATR) 1.84 2.75
MACD 0.04 -0.16
Stochastic Oscillator 38.16 72.78

Price Performance

Historical Comparison
GBX
ANAB

About GBX Greenbrier Companies Inc. (The)

Greenbrier Companies Inc supplies equipment and services to international freight transportation markets, designing and marketing freight railcars in North America, Europe, and Brazil through subsidiaries and joint ventures. It provides railcar wheel services, parts, maintenance, and conversion services in North America. The company owns a lease fleet sourced mainly from its manufacturing operations and offers railcar management, regulatory compliance, and leasing services to railroads and owners. It operates two segments: Manufacturing and Leasing & Fleet Management, with the majority of revenue from Manufacturing. The company operates in the U.S. and internationally, with the majority of revenue from the U.S. market.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: